Skip to content

Advertisement

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact us so we can address the problem.

Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling

  • 1,
  • 2,
  • 1,
  • 3,
  • 2 and
  • 1Email author
BMC Cancer201414:302

https://doi.org/10.1186/1471-2407-14-302

©  Cuenca-López et al.; licensee BioMed Central Ltd. 2014

  • Received: 20 May 2013
  • Accepted: 17 April 2014
  • Published:
Open Peer Review reports

Abstract

Background

The androgen receptor (AR) plays a central role in the oncogenesis of different tumors, as is the case in prostate cancer. In triple negative breast cancer (TNBC) a gene expression classification has described different subgroups including a luminal androgen subtype. The AR can be controlled by several mechanisms like the activation of membrane tyrosine kinases and downstream signaling pathways. However little is known in TNBC about how the AR is modulated by these mechanisms and the potential therapeutic strategists to inhibit its expression.

Methods

We used human samples to evaluate the expression of AR by western-blot and phospho-proteomic kinase arrays that recognize membrane tyrosine kinase receptors and downstream mediators. Western-blots in human cell lines were carried out to analyze the expression and activation of individual proteins. Drugs against these kinases in different conditions were used to measure the expression of the androgen receptor. PCR experiments were performed to assess changes in the AR gene after therapeutic modulation of these pathways.

Results

AR is present in a subset of TNBC and its expression correlates with activated membrane receptor kinases-EGFR and PDGFRβ in human samples and cell lines. Inhibition of the PI3K/mTOR pathway in TNBC cell lines decreased notably the expression of the AR. Concomitant administration of the anti-androgen bicalutamide with the EGFR, PDGFRβ and Erk1/2 inhibitors, decreased the amount of AR compared to each agent given alone, and had an additive anti-proliferative effect. Administration of dihydrotestosterone augmented the expression of AR that was not modified by the inhibition of the PI3K/mTOR or Erk1/2 pathways. AR expression was posttranscriptionally regulated by PI3K or Erk1/2 inhibition.

Conclusion

Our results describe the expression of the AR in TNBC as a druggable target and further suggest the combination of bicalutamide with inhibitors of EGFR, PDGFRβ or Erk1/2 for future development.

Keywords

  • Tyrosine Kinase Receptor
  • EGFR/PDFGRβ
  • PI3K-mTor
  • Erk1/2
  • TNBC (triple negative breast cancer)
  • Kinase Inhibitors
  • AR (Androgen Receptor)

Background

The understanding of the heterogeneity of cancer is of great importance for the development of effective therapeutic strategies in specific subgroups of patients. Indeed, genomic studies have classified breast cancer into different subtypes [1]. At a clinical level, this heterogeneity corresponds to different prognosis, patterns of relapse, response to treatment and clinical behavior for each breast cancer subtype. For instance, tumors expressing estrogen receptors (ER) have a more benevolent behavior compared with those overexpressing HER2 [2]. In addition, triple negative breast cancer (TNBC) shows a worse prognosis compared with tumors expressing ER, and the probability of early relapse during the first years after the diagnosed is higher compared with other subtypes [2, 3].

The influence of sex hormones in the development of breast and prostate cancer is known. Estrogens and androgens act through their receptors by a direct transcriptional regulation of genes involved in cell growth and survival [4]. In breast cancer, more than 70%–80% of tumors express the ER or progesterone receptor (PR), and therapies designed to neutralize their function have shown clinical benefit [5]. In addition the androgen receptor (AR) is expressed in breast cancer in 60%–70% of tumors regardless of the ER status [6] and has been linked with a good outcome in ER positive tumors [7]. This good prognosis is associated with the impeding of the transcriptional activity mediated by the ER [7]. By contrast, in the apocrine breast cancer subtype- an ER negative tumor- the AR acts by binding to the same transcription factors as the ER does, mainly through FOXA1, leading to a luminal gene expression phenotype [8]. In this case the expression of AR is associated with worse prognosis [8]. Recently, using gene expression analyses TNBC has been classified in subtypes including one termed luminal androgen that was enriched in genes related to this pathway [9].

Testosterone and particularly dihydrotestosterone (DHT) are the main activators of the androgen receptor [10]. Upon ligand binding AR translocate to the nucleus were it acts transcriptionally [10, 11]. Androgens are the major sex hormones in males being produced at different levels but mainly in sex-related tissues [11]. In addition, in females, androgens are also formed at the suprarenal gland, having a functional role after the deprivation of estrogens produced in the menopause [11].

The control of AR is mediated at different levels, but signalling pathways play a key role by stabilizing or enhancing its transcriptional activity. In prostate cancer, membrane receptor tyrosine kinases (RTK) have been shown to modulate the AR expression. For instance, overexpression of HER2 in cell lines of prostate cancer results in increase AR activity and stability [12]. Furthermore in breast cancer, a recent study has linked the activation of HER2 with the expression of AR [13]. Of note, the PI3K pathway is the key node for the signal transmission of the stimuli from membrane RTKs in relation to the control of the AR in prostate cancer [14, 15]. To this regard, in breast cancer, mutations at the kinase domain of the PI3KCA gene were linked with higher expression of the AR [16].

In TNBC, expression of the epidermal growth factor receptor (EGFR) or Platelet-derived Growth Factor Receptor (PDGFRβ) has been described using immunohistochemical techniques [17]. A frequent activation of the EGFR and other receptor (Met and Eph2) as well as non-receptor (Lyn, Src family kinases) tyrosine kinases has been confirmed using a profiling of tyrosine phosphorylated proteins [18]. Moreover using shRNA library screening several kinases, including the EGFR and HER2, were identified as activated in TNBC [19].

The mechanism of action of androgens in TNBC remains controversial and the relationship between activated RTKs and the expression of AR has not been fully explored, although some recent reports have suggested the AR as a potential therapeutic target [13].

In order to contribute to a better understanding of the role of AR in TNBC, the aim of this study is to evaluate the expression of the AR in TNBC and its relationship to the activation status of RTKs and its downstream routes.

Methods

Reagents and antibodies

Cell culture media and supplements (fetal bovine serum (FBS), glutamine, penicillin/streptomycin) were purchased from Invitrogen (Gaithersburg, MD). The anti-pErk1/2, anti-Erk2, anti-PDGFR β, anti-pPDGFR β, anti-EGFR and anti-pEGFR antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The anti-Akt and anti-AR antibodies were from Cell Signalling Technologies (Beverly, MA). The anti-phosphorylated Akt (Serine 473) antibody was generated against the sequence RPHFPQFpS473YSAS (p = phosphorylated) [20].

Cell culture

All cell lines were cultured at 37°C in a humidified atmosphere in the presence of 5% CO2–95% air. Cells were grown in DMEM or in RPMI medium containing a high glucose concentration (4,500 mg/liter) supplemented with antibiotics (penicillin at 100 U/ml, streptomycin at 100 μg/ml), glutamine 2 mM and 10% FBS. Cells were treated with different drugs: PD98059 (50 μM), BEZ235 (0.5 μM), BIC (20 μM), Imatinib (10 μM), Lapatinib (10 μM) and DHT (50nM).

Identification of human samples and studies

Human samples were obtained from the tumor bank of the Salamanca University Hospital and Albacete University Hospital following institutional and ethical guidelines. All patients signed the study consent form. TNBC samples were defined as those with HER2 negative by inmunohistochemistry (IHC), HER2 of 0 or 1+ or a negative fluorescence in situ hybridization (FISH). HER2 amplification (evaluated by FISH DAKO HER2 FISH pharmDxTM Kit, DakoCytomation, Glostrup, Denmark A/S) was defined as a HER2-chromosome 17 ratio of < .2.0, as required by guidelines. Hormone receptor (HR) negative was defined as follow <10% positive cells by IHC for both estrogen receptor (ER) and progesterone receptor (PR) following recommendations before 2011.

Protein extraction from human samples

Frozen human samples were inspected by haematoxylin-eosin staining for epithelial tumor content by analysis of two slices at each end of the tumor. Only samples containing 70% epithelial tumoral cells were selected for Western analyses. The tumors were minced, washed with phosphate-buffered saline (PBS), and homogenized in ice-cold lysis buffer (140 mM NaCl; 10 mM EDTA; 10% glycerol; 2% Triton X-100; 20 mM Tris pH 7.0; pepstatin, 10 mM; aprotinin, 10 mg/ml; leupeptin, 10 mg/ml; PMSF, 1 mM; beta-glycerophosphate, 25 mM; sodium fluoride, 10 mM; and sodium orthovanadate, 10 mM) with a tight-fitting Dounce homogenizer. This homogenate was centrifuged at 10,000 g for 20 minutes at 4 uC, and the supernatants were transferred to new tubes.

Antibody arrays

Two commercial arrays were used for the studies; the human phospho-RTK array kit (R&D Systems, Abingdon, United Kingdom) and the PathScan RTK Signaling Antibody Array Kit (Cell Signaling). The Image J 1.44 software (National Institute of Health, Bethesda, MD, USA) was used for the quantification of the different RTKs in the human phospho-RTK array kit, and the Odyssey V3.0 program for the quantification of the cell signalling intermediates.

Western blotting

Cells were washed with phosphate-buffered saline and lysed in ice-cold lysis buffer (140 mM NaCl, 10 mM ethylenediaminetetraacetic acid, 10% glycerol, 1% Nonidet P-40, 20 mM Tris, pH 7.0, 1 μM pepstatin, 1 μg/ml aprotinin, 1 μg/ml leupeptin, 1 mM phenylmethyl sulphonyl fluoride (PMSF), and 1 mM sodium orthovanadate) [21]. Lysates were centrifuged at 10,000 × g at 4°C for 10 min, and supernatants were transferred to new tubes. Samples were then boiled in electrophoresis sample buffer and placed on 6%–15% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) gels, depending on the molecular weight of the proteins to be analyzed. After electrophoresis, proteins in gels were transferred to polyvinylidene difluoride (PVDF) membranes (Millipore Corporation). Membranes were blocked in Tris-buffered saline with Tween 20 (TBST) (100 mM Tris [pH 7.5], 150 mM NaCl, 0.05% Tween 20) containing 1% of bovine serum albumin for 1 hour and then incubated with the corresponding antibody for 2–16 hours. After washing with TBST, membranes were incubated with HRP-conjugated anti-mouse or anti-rabbit secondary antibodies for 30 minutes and bands were visualized by using ECL Western Blotting Detection System (GE Healthcare, Buckinghamshire, United Kingdom).

Cell proliferation assays

Cells were plated in 24-well plates at 15,000–20,000 cells/well and cultured overnight in DMEM or RPMI + 10% FBS. The next day medium was replaced with DMEM or RPMI containing the different drugs. Cell proliferation was analyzed days later by an MTT-based assay as described [22]. Unless otherwise indicated, the results are presented as the mean ± standard deviation (SD) of quadruplicates of a representative experiment that was repeated at least three times.

Revere transcription (RT)-PCR

Total RNA was extracted with RNeasy Mini Kit (Quiagen) as recommended by the supplier. cDNAs were synthesized from 5 μg of total RNA by using RevertAid H Minus First Stand cDNA Synthesis Kit (Fermentas) in a total volume of 20 μl. Reverse transcription was performed at 65° for 5 min followed by 60 min at 42°. PCR reactions were performed with 2 μl cDNA in a 50 μl volume and using Taq Polymerase (Biotools) and the following primer pairs (fragments size indicated in brackets): AR (247 bp) forward 5′-CTCACCAAGCTCCTGGACTC-3′ and reverse 5′-CAGGCAGAAGACATCTGAAAG -3′, β-actin (661 bp), forward 5′-TGACGGGGTCACCCACACTGTGCCCATCTA-3′ and reverse 5′-CTAGAAGCATTTGCGGTGGACGATGGAGGG-3′. PCR cycle conditions were 1 min at 95°C, 1 min at 55°C, and 1 min at 72°C for AR and β-actin. The number of cycles was 35 and the products were resolved on a 1% agarose gel and visualized with ethidium bromide.

The design of this study is approved by the Committee of Ethics in Research of the University hospital of Albacete (Reference PI-2010/017).

Results

Expression of AR in human samples and cell lines

We used a panel of eight TNBC cell lines to evaluate the expression of the AR. Five out of eight cell lines expressed the AR, except for HBL100, HCC3153, and MDA-MB231. To corroborate these findings at a genetic level we extracted gene expression data from public libraries and evaluated the expression of the AR gene in a panel of cell lines. BT549 and HS578T (claudin-low subtype) had the highest level, HCC3153 and HCC70 (basal-like subtype) the lowest, and MDA-MB231 (claudin-low subtype) and MDA-MB435 (claudin-low subtype), had low to moderate levels (Figure 1A).
Figure 1
Figure 1

Expression of AR in a panel of TNBC cell lines and in human samples. A) Eight cell lines, Hs578T, MDA-MB231, MDA-MB435, HCC 1187, HBL 100, BT 549, HCC 70 and HCC 3153 were cultured and cell lysates were analyzed by western blot for AR expression. α-tubuline was used as a loading control. Expression of the AR gene from public gene expression profile data bases. B) Human samples of triple negative breast cancer patients were processed for protein extraction and lysates were analyzed by western blot for AR expression. α-tubuline was used as a loading control.

We next evaluated the expression of the AR in 16 human samples from triple negative breast cancer patients. As can be seen in Figure 1B the expression of the AR was observed in 5 out of 16 tumors (samples number: 2428, 37, 795, 278, 1603). Of note in three of them (samples number: 2428, 278 and 1603) the expression of the AR was high.

Expression of the androgen receptor correlates by activated receptor tyrosine kinases in human samples

Given the fact that one of the mechanisms that control the expression of the AR in prostate cancer is linked with kinase signaling pathways, we evaluated if the activation of membrane RTKs or their downstream pathways could be associated with the expression of the AR. For this purpose, we analyzed the expression of 42 RTKs and downstream effectors using phospho-specific antibody arrays in the 16 human samples from TNBC patients. Two examples are shown in Figure 2A and all date available in Additional file 1: Figure S1.
Figure 2
Figure 2

Activation of TKRs and their downstream pathways in human samples and in TNBC cell lines. A) Human samples of triple negative breast cancer patients were processed for protein extraction. Lysates containing 1 mg/ml protein were analyzed for the level of tyrosine phosphorylation in a panel of 42 receptor tyrosine kinases (RTKs) and citosolic kinases using antibody array kits. The levels of phosphorylated EGFR, HER2, HER3, PDGFRβ, Akt (S473), Akt (T308) and Erk1/2 are shown (indicated by arrows). B) Relationship between pPDGFRβ and pEGFR and AR expression in human samples. Activated PDGFRβ and EGFR obtained from the antibody array kit were measured using a gray level scale in arbitrary units. AR expression measured by western blot was classified in two groups: negative or positive. Statistical difference (p < 0.05) was analyzed using a Mann–Whitney test. C) Eight cell lines Hs578T, MDA-MB231, MDA-MB435, HCC 1187, HBL 100, BT 549, HCC 70 and HCC 3153 were cultured and cell lysates were analyzed by western blot for the levels of different proteins as well as their phosphorylated forms.

Two RTKs, the PDGFRβ and EGFR, were phosphorylated in an important number of patients (more than 20%), and their activation status correlated at a significant level with the expression of the AR measured by western-blot (Figure 2A-B) (Mann–Whitney test: EGFR and AR: p = 0.03; PDGFRβ and AR: p = 0.004). We did not identify any association between the activation status of other RTKs and the expression of the AR (data not shown). Using a similar approach we studied the kinase activation profile of proteins involved in the intracellular signaling mediated by RTKs (Figure 2A, right arm). Of note pAKT (pAKTS473, pAKTT308) and pErk1/2 were expressed in more than 40% of the samples. Indeed, pAKTS473 was expressed in around 90% of the tumors. Additional file 1: Figure S1 describes the composition of both arrays and the activation profile of these kinases. No differences were observed between any of the intracellular signaling proteins- AKT or Erk1/2- and the expression of the AR (Additional file 2: Figure S2, upper panel). This lack of association could be explained by the limited sample size used and the wide expression of these activated kinases (pAKTS473 is expressed in 90% of samples and pErk1/2 in more than 40%). However, some samples with a strong activation of pAKTS473 also showed higher expression of the AR including samples BT278, BT1603 and BT2428 (Additional file 2: Figure S2, middle and lower panel).

Activation of tyrosine kinase receptors or downstream pathways in relation to the expression of the AR in cell lines

We then studied the expression of RTKs and downstream pathways in the panel of TNBC cell lines. EGFR was activated in HCC1187, BT 549, HCC 70 and HCC 3153; and PDGFR was activated in HS578 and HCC 1187. All these cell lines described, except HCC3153, expressed the AR (Figure 2C).

In addition we studied downstream activated pathways including AKT-mTOR and Erk1/2. All cell lines had activation of pAKT except MDA-MB231. pS6 and pErk1/2 were expressed in all cell lines at different amount levels (Figure 2C). The high presence of phosphorylated AKT and Erk1/2 matched the results observed using human samples, suggesting that these cell lines could be used as a representative in vitro model. However, the increased existence of activated AKT and Erk1/2 in most of these cell lines made difficult to identify any association between the expression of the AR and the activation of these pathways.

Modulation of AR expression by pharmacological inhibition

Given the association observed between some RTKs and downstream pathways with the expression of the AR in human samples and cell lines, we evaluated if the pharmacological inhibition of these receptors could modify the expression of the AR.

For this purpose we used two cell lines; BT549, with constitutive activation of EGFR; and HS578T, with activation of PDGFRβ. Both cell lines have activation of AKT, S6 and Erk1/2, being HS578T a cell line with more activation of Erk1/2. Treatment with imatinib mesylate, a PDGFβ inhibitor, do not decreased the amount of the AR in HS578T; and a similar effect was observed for lapatinib, an EGFR inhibitor, in BT549 (Figure 3A).
Figure 3
Figure 3

Effect of PI3K/mTOR, Erk1/2 and EGFR/PDGFRβ inhibitors alone or in combination with bicalutamide on the AR expression and cell proliferation in Hs578T and BT549. A) Effect of drugs on AR expression in Hs578T and BT549. Cells were cultured and treated with drugs for 24 h. Cell lysates were analyzed by western blot for AR expression. α-tubuline was used as a loading control. B) Effect of drugs on cell proliferation in Hs578T and BT549. MTT metabolization was performed after 4 days to evaluate cell proliferation. Control cells were untreated. Statistical difference (* = p < 0.05, Bic versus control or drug combination versus drug alone.) was analyzed using a Test T. C) Effect of drugs on cell proliferation in Hs578T and BT549. Cell counting was performed after 4 days to evaluate cell proliferation. Control cells were untreated. Statistical difference (* = p < 0.05, Bic versus control or drug combination versus drug alone.) was analyzed using a Test T.

As EGFR and PDGFR signal through downstream pathways, mainly the PI3k-mTOR and the Erk1/2 pathway, and these routes have also been implicated in the androgen-independent control of the AR in prostate cancer, we evaluated if the inhibition of these central nodes could have more effect on the expression of the AR than individual inhibition of RTKs. Using the same two models, we observed that the administration of PD98059, a MEK inhibitor that inhibits Erk1/2, did not reduce the amount of the AR (Figure 3A). By contrast the PI3K-mTOR inhibitor BEZ235 reduced substantially the amount of the AR in both cell lines (Figure 3A).

We next explored the action of the anti-androgen bicalutamide when combined with inhibitors of EGFR, PDGFRβ and the PI3K-mTOR and Erk1/2 pathways. Interestingly we observed that the concomitant administration of bicalutamide with EGFR, PDGFRβ and MEK inhibitors reduced the amount of the AR compared to each agent alone (Figure 3A). This finding was not observed when combining a PI3K-mTOR inhibitor with bicalutamide.

Effects on proliferation of tyrosine kinase inhibitors alone or in combination with bicalutamide

We decided next to evaluate the effect on proliferation of pharmacological inhibitors of these receptors and pathways alone or in combination with antiandrogens. Bicalutamide alone reduced the MTT uptake in both cell lines (Figure 3B). Interestingly, in both cell lines the combination of bicalutamide with MEK inhibition was able to produce a greater anti-proliferative effect than each agent given alone (p < 0.05). Interestingly, this combination effect was not observed for BEZ235. In HS578T, imatinib was unable to reduce the MTT uptake but increased the anti-proliferative effect of bicalutamide; and in BT549 lapatinib augmented the action of bicalutamide in a similar manner (Figure 3B). A similar effect was observed counting cells (Figure 3C).

Action of DHT on the expression of the AR

We then evaluated the action of DHT and bicalutamide on the expression of AR and how the inhibition of these kinases can modulate its expression. Interestingly administration of DHT increased the amount of the AR in HS578T and BT549 (Figure 4A). Administration of bicalutamide did not reduce the expression of the AR when given alone or in combination with DHT in BT549. However, in HS578T bicalutamide partially prevented the amount increase of the AR in the presence of DHT (Figure 4A). The amount of the AR gene measured by polymerase chain reaction (PCR), were not modified by the administration of DHT suggesting that this is a posttranscriptional mechanism (Figure 4B). When we evaluated the action of Erk1/2 and PI3K inhibitors on the expression of AR after stimulation with DHT, we observed that the concomitant administration of BEZ235 was not able to reduce AR expression as observed previously when given alone (Figure 3). In the presence of DHT, only bicalutamide is able to reduce the expression of AR produced by DHT (Figure 4A). Similarly, BEZ235 or PD98059 given alone; or BEZ235 and PD98059 in combination with bicalutamide did not modify the amount of the AR gene (Figure 4B).
Figure 4
Figure 4

Effect of DHT and bicalutamide alone and in combination with PI3K/mTOR, Erk1/2 and EGFR/PDGFRβ inhibitors in AR expression and cell proliferation. A) Effect of DHT and bicalutamide, BEZ and PD in alone and combined on AR expression in Hs578T and BT549. Cells were cultured and treated with drugs for 24 h. Cell lysates were analyzed by western blot for AR expression. α-tubuline was used as loading control. B) In parallel, total RNA was extracted and subjected to RT-PCR. Subsequently, amplification products were resolved on agarose gel to determine AR mRNA levels. Actin was used as protein loading control and mRNA as gene control.

Discussion

In the present work, we describe the expression of the AR in TNBC and its relation to RTKs and their downstream signal routes. It is also interesting to remark that the expression of the AR was studied in cell lines not representative of a luminal androgen receptor gene expression subtype [9].

In prostate cancer evidence support the link between the activation of RTKs, like the insulin-like growth factor, keratinocyte growth factor, EGFR or HER2, and the transactivation of the AR in the absence of androgens [12, 23, 24]. Particularly signaling through ErbB receptors and HER2 augment the transcription of the AR; and activation of HER2 and HER3 through the HER3-ligand Neuregulin increases the amount of the AR [12, 23]. Therefore inhibition of these kinases sensitizes cells to androgen withdrawal [23, 25]. In estrogen negative breast cancer, the AR regulates the HER2 function suggesting that antiandrogens is a potential therapeutic approach [13]. Indeed, studies in breast cancer using human samples confirm that those tumors that are HER2 positive express higher amounts of the AR [26].

In our study we show a correlation between activated membrane tyrosine kinase receptors and the expression of the AR in TNBC. It is known that in triple negative tumors EGFR and PDGFRβ are phosphorylated and present in a significant number of tumors [19, 27]. If extrapolating from mechanisms observed in prostate cancer, is not surprising to identify a correlation between activated RTKs and the expression of the AR. Interestingly this association was also observed in a panel of cell lines, and treatment with specific tyrosine kinase inhibitors against them reduced slightly the amount of the AR, particularly with lapatinib in BT549 when combined with bicalutamide. A slightly similar effect was observed for imatinib and bicalutamide in HS578T. As the PI3K/AKT pathway and the MAPK pathway are key intracellular signaling nodes from RTKs, we decided to evaluate their role in the activation of the AR. It is known that targeting key nodes has a more profound effect on the inhibition of deregulated functions that the inhibition of single receptors [28]. In prostate cancer the PI3K/AKT pathway has been described as a key regulator in the transcription of the AR [12], and in breast cancer mutations at the PIK3CA gene were associated with expression of the AR in patients [16]. Our results show that the inhibition of the PI3K/mTOR pathway with BEZ235 decreased the amount of the AR in the absence of androgens.

It was interesting to find how the concomitant administration of an Erk1/2 inhibitor with bicalutamide reduced the amount of the AR in a more profound manner than when each agent was given alone. This effect was also observed when using inhibitors of EGFR and PDGFRβ.

We then studied the effect on proliferation of these combinations. Although an important effect was noted with BEZ235 given alone, no effect on proliferation was found when associated with an anti-androgen. Furthermore, the concomitant administration of PD98059 plus bicalutamide produced a profound arrest in proliferation compared to each agent given alone. This effect suggests that the inhibition of the MAPK pathway facilitates the anti-proliferative effect of anti-androgens. A synergistic interaction between anti-androgens and Erk1/2 inhibitors has been described in other models including apocrine breast cancer, but not in TNBC [29]. A similar result was observed for the combination of lapatinib and bicalutamide in BT549 and for imatinib in HS578T.

Stimulation with DHT increased the amount of the AR, and this was not prevented by the administration of either an inhibitor of PI3K or Erk1/2; showing that the mechanism associated with the expression of the AR by androgens is independent of a kinase control. Furthermore, effects on the expression of AR after stimulation with DHT or when administering kinase inhibitors were independent of the expression of the AR gene, suggesting a posttranscriptional mechanism.

Our findings have some potential therapeutic translations. It has been suggested that the AR is a potential druggable target in TNBC and indeed, clinical studies are currently evaluating the role of androgen deprivation in the treatment of patients with breast cancer [30]. In our work we identify a relationship between the expression of the AR and the activation of membrane kinases like EGFR and PDGFRβ. Furthermore, the concomitant inhibition EGFR and PDGFRβ with bicalutamide increased the antiproliferative effect compared with each agent given alone. A similar effect was observed for the administration of the Erk1/2 inhibitor with bicalutamide.

Conclusions

We observed a positive correlation between the activation of EGFR and PDGFRβ and the expression of the AR. Inhibition of PI3K pathway decreased the total amount of the AR. Inhibition of Erk1/2, PDGFRβ and EGFR decreased the expression of the AR when given concomitantly with bicalutamide and had an additive anti-proliferative effect, suggesting that administration of anti-androgens in TNBC should be given concomitantly with inhibitors of these kinases. Modification of AR expression by these kinase inhibitors was posttranscriptionally regulated. In conclusion, our results describe mechanisms associated with the control of the AR expression in TNBC, and demonstrate a potential therapeutic opportunity for the combination of anti-androgens with RTK inhibitors and its downstream routes.

Declarations

Acknowledgements

This research is supported by: Fundación Sociosanitaria de Castilla La Mancha (FISCAM) Grant Number. PI/2010/017, Ministerio de Ciencia e Innovación, Grant Number BFU2009-07728/BMC, Fondo de Investigación Sanitaria (FIS), Grant Number PI09/02144, Cancer Center Network Program from the ISCIII (RD06/0020/0041). Fundación Científica AECC.

Authors’ Affiliations

(1)
Translational Cancer Research Unit, Albacete University Hospital, 02006 Albacete, Spain
(2)
Salamanca Cancer Research Center-CSIC, Salamanca, Spain
(3)
Vall D’Hebron Institute of Oncology (VHIO), Barcelona, Spain

References

  1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature. 2000, 406: 747-752. 10.1038/35021093.View ArticlePubMedGoogle Scholar
  2. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001, 98: 10869-10874. 10.1073/pnas.191367098.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007, 13: 4429-4434. 10.1158/1078-0432.CCR-06-3045.View ArticlePubMedGoogle Scholar
  4. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC: Production and actions of estrogens. N Engl J Med. 2002, 346: 340-352. 10.1056/NEJMra000471.View ArticlePubMedGoogle Scholar
  5. Smith IE, Dowsett M: Aromatase inhibitors in breast cancer. N Engl J Med. 2003, 348: 2431-2442. 10.1056/NEJMra023246.View ArticlePubMedGoogle Scholar
  6. Agoff SN, Swanson PE, Linden H, Hawes SE, Lawton TJ: Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol. 2003, 120: 725-731. 10.1309/42F00D0DJD0J5EDT.View ArticlePubMedGoogle Scholar
  7. Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, Jindal S, Segara D, Jia L, Moore NL, Henshall SM, Birrell SN, Coetzee GA, Sutherland RL, Butler LM, Tilley WD: Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res. 2009, 69: 6131-6140.View ArticlePubMedGoogle Scholar
  8. Robinson JL, Macarthur S, Ross-Innes CS, Tilley WD, Neal DE, Mills IG, Carroll JS: Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J. 2011, 30: 3019-3027. 10.1038/emboj.2011.216.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011, 121: 2750-2767. 10.1172/JCI45014.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Hickey TE, Robinson JL, Carroll JS, Tilley WD: Minireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?. Mol Endocrinol. 2012, 26: 1252-1267. 10.1210/me.2012-1107.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Kotsopoulos J, Narod SA: Androgens and breast cancer. Steroids. 2012, 77: 1-9. 10.1016/j.steroids.2011.10.002.View ArticlePubMedGoogle Scholar
  12. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL: HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell. 2004, 6: 517-527. 10.1016/j.ccr.2004.09.031.View ArticlePubMedGoogle Scholar
  13. Ni M, Chen Y, Lim E, Wimberly H, Bailey ST, Imai Y, Rimm DL, Shirley Liu X, Brown M: Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell. 2011, 20: 119-131. 10.1016/j.ccr.2011.05.026.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Rosen N, Sawyers CL: Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011, 19: 575-586. 10.1016/j.ccr.2011.04.008.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Mehrian-Shai R, Chen CD, Shi T, Horvath S, Nelson SF, Reichardt JK, Sawyers CL: Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci U S A. 2007, 104: 5563-5568. 10.1073/pnas.0609139104.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, Carey M, Agarwal R, Meric-Berstam F, Traina TA, Hudis C, Hortobagyi GN, Gerald WL, Mills GB, Hennessy BT: Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res. 2009, 15: 2472-2478. 10.1158/1078-0432.CCR-08-1763.View ArticlePubMedGoogle Scholar
  17. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004, 10: 5367-5374. 10.1158/1078-0432.CCR-04-0220.View ArticlePubMedGoogle Scholar
  18. Hochgrafe F, Zhang L, O’Toole SA, Browne BC, Pinese M, Porta Cubas A, Lehrbach GM, Croucher DR, Rickwood D, Boulghourjian A, Shearer R, Nair R, Swarbrick A, Faratian D, Mullen P, Harrison DJ, Biankin AV, Sutherland RL, Raftery MJ, Daly RJ: Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. Cancer Res. 2010, 70: 9391-9401. 10.1158/0008-5472.CAN-10-0911.View ArticlePubMedGoogle Scholar
  19. Sun T, Aceto N, Meerbrey KL, Kessler JD, Zhou C, Migliaccio I, Nguyen DX, Pavlova NN, Botero M, Huang J, Bernardi RJ, Schmitt E, Hu G, Li MZ, Dephoure N, Gygi SP, Rao M, Creighton CJ, Hilsenbeck SG, Shaw CA, Muzny D, Gibbs RA, Wheeler DA, Osborne CK, Schiff R, Bentires-Alj M, Elledge SJ, Westbrook TF: Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell. 2011, 144: 703-718. 10.1016/j.cell.2011.02.003.View ArticlePubMedGoogle Scholar
  20. Montero JC, Seoane S, Ocana A, Pandiella A: P-Rex1 participates in Neuregulin-ErbB signal transduction and its expression correlates with patient outcome in breast cancer. Oncogene. 2011, 30: 1059-1071. 10.1038/onc.2010.489.View ArticlePubMedGoogle Scholar
  21. Diaz-Rodriguez E, Cabrera N, Esparis-Ogando A, Montero JC, Pandiella A: Cleavage of the TrkA neurotrophin receptor by multiple metalloproteases generates signalling-competent truncated forms. Eur J Neurosci. 1999, 11: 1421-1430. 10.1046/j.1460-9568.1999.00552.x.View ArticlePubMedGoogle Scholar
  22. Yuste L, Montero JC, Esparis-Ogando A, Pandiella A: Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin. Cancer Res. 2005, 65: 6801-6810. 10.1158/0008-5472.CAN-04-4023.View ArticlePubMedGoogle Scholar
  23. Gregory CW, Whang YE, McCall W, Fei X, Liu Y, Ponguta LA, French FS, Wilson EM, Earp HS: Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res. 2005, 11: 1704-1712. 10.1158/1078-0432.CCR-04-1158.View ArticlePubMedGoogle Scholar
  24. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H: Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 1994, 54: 5474-5478.PubMedGoogle Scholar
  25. Chen L, Mooso BA, Jathal MK, Madhav A, Johnson SD, van Spyk E, Mikhailova M, Zierenberg-Ripoll A, Xue L, Vinall RL, DeVere White RW, Ghosh PM: Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3. Clin Cancer Res. 2011, 17: 6218-6228. 10.1158/1078-0432.CCR-11-1548.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Park S, Koo J, Park HS, Kim JH, Choi SY, Lee JH, Park BW, Lee KS: Expression of androgen receptors in primary breast cancer. Ann Oncol. 2010, 21: 488-492. 10.1093/annonc/mdp510.View ArticlePubMedGoogle Scholar
  27. Montero JC, Esparis-Ogando A, Re-Louhau MF, Seoane S, Abad M, Calero R, Ocana A, Pandiella A: Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer. Oncogene. 2014, 33: 148-156. 10.1038/onc.2012.572.View ArticlePubMedGoogle Scholar
  28. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C, Chin L, DePinho RA: Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science. 2007, 318: 287-290. 10.1126/science.1142946.View ArticlePubMedGoogle Scholar
  29. Naderi A, Chia K, Liu J: Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer. Breast Cancer Res. 2011, 13: R36-10.1186/bcr2858.View ArticlePubMedPubMed CentralGoogle Scholar
  30. Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast Cancer. [http://www.clinicaltrial.gov/ct2/show/NCT00755885?term=abiraterone+and+breast&rank=2]

    31. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/14/302/prepub

Copyright

© Cuenca-López et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

Advertisement

BMC Cancer

ISSN: 1471-2407

Contact us